The new Start dressing range--Urgotul Start, UrgoCell Start.
Delayed wound healing has implications both for the clinician and the patient, as well as having a financial burden on the National Health Service. UrgoCell Start and Urgotul Start are the first dressings on the drug tariff to be impregnated with Nano-OligoSaccharide Factor (NOSF), a new compound that aims to promote wound closure through the inhibition of matrix metalloproteinase (MMP) activity. The dressings are designed to 'kick-start' wounds that are at risk of delayed healing. there is good clinical evidence, comprising multi-centre Randomized Controlled Trials, an observational study and case studies, to support the process of MMP inhibition and its clinical efficacy in kick-starting wound healing.
Powell
Gail
G
Wound Care Service, Bristol Primary Care Trust, Community Health, Knowle Clinic, Broadfield, Knowle, Bristol.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D047070:Bandages, Hydrocolloid; D055317:Evidence-Based Practice; D005260:Female; D006801:Humans; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000187:drug effects / Q000502:physiology; D015337:Multicenter Studies as Topic; D009730:Nursing Assessment; D009844:Oligosaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D017592:Skin Care / Q000379:methods / Q000451:nursing; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology; D014947:Wounds and Injuries / Q000517:prevention & control*
D061965:Matrix Metalloproteinase Inhibitors; D009844:Oligosaccharides; D020782:Matrix Metalloproteinases